Healthcare Industry News: Occlutech
News Release - June 2, 2016
Occlutech Obtains European CE Mark Approval for its LAA OccluderSCHAFFHAUSEN, Switzerland, June 2, 2016 -- (Healthcare Sales & Marketing Network) -- Occlutech, a leading innovator of implants to treat structural heart disease, today announced that it has obtained European CE Mark approval for its Left Atrial Appendage (LAA) occluder. The device is a specifically designed implant for the minimally invasive closure of the LAA, a procedure that minimizes the risk of strokes in patients suffering from atrial fibrillation.
Tor Peters, CEO of Occlutech Group, commented: "We are extremely pleased to be able to provide patients and cardiologists with this innovative product and expect our LAA occluder to significantly add and improve therapy options for patients."
The Occlutech LAA occluder consists of a flexible nitinol wire mesh with a unique loop anchoring technology and sealing properties. The special design provides properties that enhance flexibility and adaptability resulting in a high rate of acute closure.
Occlutech is a global leader in developing innovative products for the treatment of structural heart disease. The Company sells and markets ASD, PFO, PLD, VSD, PDA and LAA occluders, as well as a range of specialized occlusion devices and accessories in over 80 countries around the world. Occlutech has various innovative products under development and operates facilities in Germany, Turkey and Sweden. For additional information please visit Occlutechīs website at http://www.Occlutech.com .
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.